JAPT Rec'd PCT/PTO 31 MAR 2006

FILING BY "EXPRESS A EV 70460817 US

20. Other items or information:

March 31, 7006

Date of Deposit

Form PTO-1390-MOD (REV 10-96)			Department of Commerce Palent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33373-US-PCT	
TRANSMITTAL LETTER TO THE UNITED STATES			HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
		DESIGNATED/ELECTED O	10/574536		
		<b>CONCERNING A FILING UN</b>		801914956	
			INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
		P2004/011054	4 October 2004 (04.10.04)	3 October 2003 (03.10.03)	
		IN SUBSTITUTED SPIROCYCLIC LA	CTAMS AND USE THEREOF AS F	PHARMACEUTICALS	
AP	PLIC	ANT(S) FOR DO/EO/US			
AU	BER	SON ET AL.		<del></del>	
App	licar	t herewith submits to the United States De	esignated/Elected Office (DO/EO/US) th	ne following items and other information:	
1. 2.	$\square$	This is a FIRST submission of items cond	erning a filing under 35 U.S.C. 371.	der 35 I I S.C. 371	
3.		This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay			
4.	$\boxtimes$	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
		a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau). b. ☑ has been transmitted by the International Bureau. (See Form PCT/IB/308)			
_		c.  is not required, as the application	was filed in the United States Receiving	g <sup>´</sup> Office (RO/US).	
6. 7.		A translation of the International Applicati Amendments to the claims of the Internat		(35 U.S.C.371(c)(3)).	
• •		a.   are transmitted herewith (required	d only if not transmitted by the Internation	onal Bureau).	
		b. have been transmitted by the Inte	ernational Bureau. Le time limit for making such amendmer	nts has NOT expired.	
_		d. 🛛 have not been made and will not be made.			
8. 9.		A translation of the amendments to the cl An executed Declaration and Power of At	aims under PCT Article 19 (35 U.S.C. 3 tornev (original or copy) (35 U.S.C. 371	(c)(3)). (c)(4)).	
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 L				under PCT Article 36 (35 U.S.C.	
371(c)(5)).					
Items 11. to 16. below concern document(s) or information included.					
11.	$\boxtimes$	An Information Disclosure Statement und	er 37 CFR 1.97 and 1.98.		
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13.	$\square$	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.			
14.	$\boxtimes$	An Application Data Sheet under 37 CFR 1.76.			
15.		A substitute specification.			
16.		A change of power of attorney and/or address letter.			
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.			
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).			
19.		A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).			

U.S. APPLICATION NO. 16 kpcvm, sep-37 CER 15) 5 3 6 INTERNATIONAL APPLICATION NO. PCT/EP2004/011054 33373-US-I	PCT					
The following fees are submitted:	CALCULATIONS PTO USE					
	ONLY					
21. Sasic national fee\$300						
22. Examination Fee  If International preliminary examination report was prepared by USPTO						
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$						
. All other situations						
23. Search fee						
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international						
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400						
All other situations						
TOTAL OF 21, 22 AND 23 =	\$ 900					
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer						
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
Total Sheets Extra sheets Number of each additional 50 or fraction RATE thereof (round up to a whole number)						
26 - 100 =   /50 =   0   X \$ 250	\$					
Surcharge of <b>\$130</b> for furnishing the oath of declaration later than	\$					
months from the earliest claimed priority date (37 CFR 1.492(e)).  CLAIMS NUMBER FILED NUMBER EXTRA RATE						
CLAIMS         NUMBER FILED         NUMBER EXTRA         RATE           Total claims         10         - 20 =         0         X         \$ 50	\$					
Independent claims 1 - 3 = 0 X \$ 200	\$					
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360   TOTAL OF ABOVE CALCULATIONS =	\$ \$ 900					
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be	•					
filed (Note 37 CFR 1.9, 1.27, 1.28).	\$ 900					
Processing fee of \$130 for furnishing the English translation later than 30 months from the						
earliest claimed priority date (37 CFR 1.492(f)). + TOTAL NATIONAL FEE =	\$ 900					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied	<del>*************************************</del>					
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +	\$ \$ 900					
TOTAL FEES ENCLOSED =						
	Amount to   \$ be: refunded					
	charged \$					
a. A check in the amount of \$ to cover the above fees is enclosed.						
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.						
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending states.						
Send all correspondence to the address associated with Customer No. 001095, which is currently:						
Peter J. Waibel						
Novartis Attorney for Applicants	i					
Corporate Intellectual Property Reg. No. 43,228 One Health Plaza, Building 104 (862) 778-7951						
East Hanover, NJ 07936-1080						